深圳迈瑞生物医疗电子股份有限公司 股东会议事规则（草案） （H 股发行并上市后适用） 前述第（三）项持股股数按股东提出书面要求日计算。 2 第一章 总 则 公司董事会应当切实履行职责，认真、按时组织股东会。公司全体董事应当 勤勉尽责，确保股东会正常召开和依法行使职权。 1 第一条 为维护深圳迈瑞生物医疗电子股份有限公司（以下简称"公司"）及公司股东 的合法权益，明确股东会的职责权限，提高股东会议事效率，保证股东会依 法行使职权，根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会 规则》《深圳证券交易所创业板股票上市规则》《香港联合交易所有限公司 证券上市规则》（以下简称"《香港上市规则》"）、《深圳证券交易所上市 公司自律监管指引第 2 号—创业板上市公司规范运作》《深圳证券交易所创 业板上市公司自律监管指南第 1 号—业务办理》等法律、法规、规范性文件 以及《深圳迈瑞生物医疗电子股份有限公司章程》（以下简称"《公司章程》"） 等有关规定，结合公司的实际情况，特制定本规则。 第二条 公司股东会的召集、提案、通知、召开等事项适用本规则。 ...

Core Viewpoint - The company, Mindray Medical (300760.SZ), is experiencing significant growth in its in-vitro diagnostic (IVD) business in the Czech Republic, with increasing sales and market share across various product lines [1] Group 1: Business Progress in Czech Republic - The sales revenue and market share of Mindray's IVD business in the Czech Republic are increasing year by year [1] - The company has achieved a 25% market share in hematology products, which are considered core products [1] - Mindray's products have been installed in private chain groups such as AKESO, IFCOR, and Kli**cka Biochemia, indicating strong market penetration [1] Group 2: Product Line Expansion - Mindray has made breakthroughs in various product lines including hematology, biochemistry, immunology, urinalysis, and flow cytometry [1] - The M980 chemical immunoassay cascade line has been installed at **BH Olomouc Hospital, showcasing the company's technological advancements [1] - Other diagnostic products have been installed in teaching hospitals such as Nemocnice Na Homolce and Fakultní nemocnice Brno, reflecting a comprehensive expansion of the IVD product lines [1]

Core Insights - Company anticipates that by the first half of 2025, international revenue will account for approximately 50% of total revenue, with international in vitro diagnostics contributing 29% and high-potential segments like international animal healthcare and minimally invasive surgery making up 12% of international revenue [1][2] - The company has been actively pursuing overseas markets for 25 years, aiming for international revenue to eventually reach 70% of total revenue, with current international market share at only 2-3% [2] - The company is focusing on deeper localization strategies to meet high-end customer demands and local government requirements, with plans for localized production bases in 14 countries, 11 of which have already commenced production [2] Market Position and Strategy - The company believes that the international market size is significantly larger than the domestic market, justifying the expectation for international revenue to exceed 50% of total revenue [2] - The company emphasizes the importance of adapting to changing international conditions and leveraging its experience and resources to seize potential opportunities [3] - The company maintains confidence in its ability to deliver stable operating performance and healthy profit levels, which are essential for long-term investor returns and market recognition [3]

Core Viewpoint - Mindray Medical has significantly improved its understanding and adaptability to policies such as centralized procurement, enhancing its execution capabilities in policy implementation [1] Group 1: Policy Adaptation - The company has strengthened its ability to interpret and adapt to various policies over the past few years, leading to improved timeliness in policy interpretation and proactive compliance [1] - Mindray's proactive approach to policy changes is expected to provide a solid foundation for executing its strategies in response to evolving healthcare policies [1] Group 2: Market Position and Financials - Centralized procurement has led to a substantial increase in the company's domestic market share, while its gross profit margin has remained relatively stable [1] - The key to this stability in gross profit margin is attributed to the company's mastery of core technologies [1] Group 3: Future Outlook - The domestic market is anticipated to continue embracing changes in medical insurance policies, and the company aims to actively adapt to these changes to seize opportunities for better development [1]

Core Viewpoint - Company aims to increase international revenue to approximately 50% of total revenue by mid-2025, with a focus on expanding its presence in overseas markets and enhancing local production capabilities [1] Revenue Breakdown - As of now, international revenue accounts for about 50% of the company's overall revenue, with international in vitro diagnostics contributing 29% and international animal healthcare and minimally invasive surgery accounting for 12% of international revenue [1] Future Development Direction - The company plans to maintain a strong focus on international markets, particularly in developing countries, which are expected to grow rapidly [1] - The long-term goal is for international revenue to reach 70% of total revenue, supported by deeper localization efforts and a robust response to changing international conditions [1] Market Position and Strategy - Despite having a market share of only 2-3% in overseas markets, the company believes that the international market potential is significantly larger than the domestic market [1] - The company has established localized production bases in 14 countries, with 11 already in operation, to meet high-end customer demands and comply with local government requirements [1] Stock Performance Insights - Stock price fluctuations are influenced by various factors including company performance, macroeconomic conditions, industry policies, and market sentiment, rather than a single factor [1] - The company expresses confidence in its ability to deliver stable operating performance and healthy profit levels, which are essential for long-term investor returns and market recognition [1]

Core Viewpoint - The company has strengthened its understanding and adaptability to policies such as centralized procurement, which has significantly improved its domestic market share without a substantial change in gross margin [1] Group 1: Company Response to Investor Inquiry - The company acknowledges the impact of centralized procurement on its operations and emphasizes its proactive approach to policy changes [1] - The company has enhanced its execution capabilities regarding policy implementation, ensuring timely interpretation and active compliance with regulations [1] - The company believes that its mastery of core technologies has been crucial in maintaining stable gross margins despite increased market share [1] Group 2: Future Outlook - The company is committed to adapting to long-term changes in healthcare insurance policies in the domestic market [1] - The company aims to seize opportunities arising from policy changes to achieve better development in the future [1]

Core Viewpoint - The article discusses the performance of the Chuangye 50 ETF (159682) and its major holdings, highlighting a positive market trend with notable gains in several key stocks [1]. Group 1: ETF Performance - The Chuangye 50 ETF (159682) opened with a gain of 1.07%, priced at 1.415 yuan [1]. - Since its inception on December 23, 2022, the fund has achieved a return of 40.16% [1]. - The fund's performance over the past month has been a return of 2.06% [1]. Group 2: Major Holdings - Key stocks in the Chuangye 50 ETF include: - Ningde Times, which opened with a gain of 1.74% [1]. - Dongfang Wealth, up by 0.31% [1]. - Huichuan Technology, increasing by 1.21% [1]. - Zhongji Xuchuang, rising by 2.12% [1]. - Mindray Medical, gaining 1.06% [1]. - Xinyi Sheng, up by 2.04% [1]. - Sunshine Power, increasing by 2.56% [1]. - Shenghong Technology, rising by 2.95% [1]. - Yiwei Lithium Energy, up by 0.10% [1]. - Tonghuashun, gaining 0.56% [1]. Group 3: Management Information - The Chuangye 50 ETF is managed by Invesco Great Wall Fund Management Co., Ltd. [1]. - The fund managers are Wang Yang and Zhang Xiaonan [1].

风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 10月14日，双创龙头ETF（588330）开盘涨0.78%，报0.904元。双创龙头ETF（588330）重仓股方面， 宁德时代开盘涨1.74%，中芯国际涨0.36%，迈瑞医疗涨1.06%，海光信息涨1.97%，中际旭创涨2.12%， 寒武纪涨0.78%，新易盛涨2.04%，汇川技术涨1.21%，阳光电源涨2.56%，澜起科技涨2.15%。 双创龙头ETF（588330）业绩比较基准为中证科创创业50指数收益率，管理人为华宝基金管理有限公 司，基金经理为胡洁，成立（2021-06-29）以来回报为-10.24%，近一个月回报为3.88%。 来源：新浪基金∞工作室 ...

Summary of Conference Call Notes Industry Overview - **Industry**: China Healthcare - **Quarter**: 3Q25 Key Companies and Revenue Growth Companies with Higher Revenue Growth 1. **United Imaging** - Expected revenue growth: **44% YoY** in 3Q25 - Growth driven by improved hospital bidding data in China [1][6] 2. **Lepu** - Expected revenue growth: **38% YoY** in 3Q25 - Growth factors: - Low base effect from 3Q24 due to "Four Same" policy impacting pharmaceutical business - Incremental revenue from consumer healthcare segment, particularly medical aesthetics [1][6] 3. **Gan & Lee Pharmaceuticals** - Expected revenue growth: **23% YoY** in 3Q25 - Benefits from insulin VBP renewal and progress in overseas expansion [1][6] Companies Under Pressure 1. **Zhifei** - Currently in the trough of its revenue cycle - Revenue expected to decline by **30% YoY** in 3Q25 - Increased competition following Wantai's launch of a 9-valent HPV vaccine - Offering discounts to accelerate inventory destocking [2][6] 2. **ICL Companies (Kingmed and Dian Diagnostics)** - Expected to post negative revenue growth in 3Q25 - Industry pricing pressure has stabilized, indicating potential for positive growth in 4Q25 [2][6] Financial Estimates and Changes - **Tonghua Dongbao**: Revised annual earnings estimates upward due to market share gains post-insulin VBP renewal [7] - **Kelun**: Revised net profit estimates downward due to ongoing price war in the API industry, while revenue estimates remain unchanged [7][10] Detailed Financial Estimates Exhibit 1: Revenue and Earnings Growth Preview - **United Imaging**: Revenue from **1,621 million** to **2,327 million** (44% YoY) - **Lepu**: Revenue from **1,402 million** to **1,937 million** (38% YoY) - **Gan & Lee**: Revenue from **930 million** to **1,140 million** (23% YoY) - **Zhifei**: Revenue from **4,528 million** to **3,177 million** (-30% YoY) [6] Exhibit 2: Updated Estimates for Tonghua Dongbao (2025E to 2027E) - **Revenue**: Increased from **2,612 million** to **2,689 million** (3.0% change) - **Net Profit**: Increased from **401 million** to **408 million** (1.5% change) [8] Exhibit 3: Updated Estimates for Kelun (2025E to 2027E) - **Revenue**: Remains at **19,029 million** (0.0% change) - **Net Profit**: Decreased from **2,791 million** to **2,686 million** (-3.8% change) [10] Risks and Methodology - **Mindray**: Target price of **Rmb314** with risks including VBP impacts and market penetration challenges [12][13] - **SNIBE**: Target price of **Rmb73** with risks from competition and policy changes [14] - **Hualan**: Target price of **Rmb19** with risks from regulatory changes and competition [15] - **Tonghua Dongbao**: Neutral rating with target price of **Rmb9**, risks from product sales ramp-up and competition [17] - **Kelun**: Neutral rating with target price of **Rmb38**, risks from API price declines [18] Conclusion - The China healthcare sector is experiencing varied growth dynamics, with certain companies like United Imaging and Lepu showing strong revenue growth, while others like Zhifei face significant challenges. The financial estimates reflect these trends, with adjustments made based on market conditions and competitive pressures.

Market Overview - The medical device sector experienced a decline of 1.35% on October 13, with Nanwei Medical leading the drop [1] - The Shanghai Composite Index closed at 3889.5, down 0.19%, while the Shenzhen Component Index closed at 13231.47, down 0.93% [1] Top Performers - Zhendemedical (603301) saw a closing price of 60.44, with a rise of 7.05% and a trading volume of 166,300 shares [1] - Wuzhou Medical (301234) closed at 46.22, up 6.13%, with a trading volume of 32,400 shares [1] - BGI Genomics (688114) closed at 72.35, increasing by 4.99% with a trading volume of 89,300 shares [1] Underperformers - Nanwei Medical (688029) closed at 91.15, down 6.78% with a trading volume of 42,800 shares [2] - Kangzhong Medical (688607) closed at 26.57, down 4.60%, with a trading volume of 25,700 shares [2] - Mindray Medical (300760) closed at 235.20, down 2.81%, with a trading volume of 108,600 shares [2] Capital Flow - The medical device sector saw a net outflow of 412 million yuan from institutional investors, while retail investors contributed a net inflow of 325 million yuan [2][3] - The top net inflow from retail investors was observed in Mindray Medical, with 2.63 million yuan, while Zhendemedical experienced a net outflow of 55.19 million yuan from retail investors [3]